To foster cross - disciplinary collaboration and knowledge exchange, and to integrate the professional resources of both parties, RocRock Bio and Shandong Port Medical and Health Management Group held a special expert signing ceremony at Qingdao Fuwai Hospital on June 8th. Professor Xiushan Yin, co-founder and CEO of RocRock Bio, was appointed as a distinguished expert in research and regenerative medicine. The ceremony was attended by RocRock Bio's CEO Xiushan Yin, members of RocRock Bio's research team, Jinhuawei, Party Secretary and Chairman of the Medical and Health Management Group, Yu Chao, Party Secretary and General Manager of the Medical and Health Management Group, and Li Jiongyi, Party Secretary and Chairman of Qingdao Fuwai Hospital.
This event signifies a new phase of cooperation between the two parties, focusing on advancing the development of CAR-M therapies for solid tumors.
(Signing ceremony)
During the meeting, both parties agreed to collaborate closely in research and regenerative medicine. They will work together to enhance research standards, develop innovative CAR-M therapies for solid tumors, and advance medical technologies in cellular molecular biology and gene detection. This comprehensive partnership is designed to fast-track the development of cell-based treatments for solid tumors. Through resource sharing and joint efforts, the parties aim to conduct experiments and analyze data more efficiently, thereby accelerating the development and clinical use of these promising therapies.
(Signing ceremony)
Following the signing ceremony, both parties carried out on - site inspections for the construction and site selection of the comprehensive cell resource bank. Xiushan Yin, CEO of RocRock Bio, put forward constructive opinions and suggestions on the construction of the cell comprehensive laboratory and the next steps in scientific research work.
(Contracted special expert)
This signing ceremony signifies the commencement of our collaborative journey and shared vision for the future. Moving forward, both parties will focus on accelerating the development of a comprehensive cell resource bank. This initiative encompasses the establishment of five specialized centers: regional cell storage, cell preparation, cell tissue engineering, biosample storage, and gene engineering. These centers will play a pivotal role in driving the rapid and sustainable growth of the cell therapy and regenerative medicine sector. By collaborating with Shandong Medical and Health Group, RocRock Bio gains valuable insights into clinical demands and patient treatment challenges. This understanding enables the company to develop and enhance cell-based therapeutic solutions in a targeted manner. This in-depth partnership not only creates more clinical trial opportunities but also speeds up the market launch and practical application of cell-based drugs. Through resource integration, knowledge sharing, and cross-disciplinary collaboration, we aim to fast-track the clinical application of cell-based therapy research for solid tumors, drive innovation in solid tumor treatment, provide more effective options for patients, and advance medical technology.
The Shandong Port Group, a significant state-owned enterprise in Shandong Province, was established on August 6, 2019, and is headquartered in Qingdao. It oversees four major port groups: Qingdao Port Group, Rizhao Port Group, Yantai Port Group, and Bohai Bay Port Group. The group also has three listed companies: Qingdao Port (601298.SH, 06198.HK), Rizhao Port (600017.SH), and Rizhao Port (6117.HK), and thirteen sector groups including investment and holding, port construction, urban integration, logistics, shipping, cruise tourism, equipment, trade, technology, overseas development, vocational education, medical care, and port services.
Currently, Shandong Port Group has formed an integrated development pattern with Qingdao Port as the leader, Rizhao Port and Yantai Port as the two wings, Bohai Bay Port as the extension, and the various sector groups as the support, relying on numerous inland ports. In 2022, the port handled over 1.6 billion tons of cargo and over 37 million TEUs of containers. The group adheres to the principle of mutual benefit between the east and west, both domestically and internationally, and is committed to building world-class marine ports that connect four seas, link eight directions, and enjoy a good reputation globally.
Shandong Port Medical and Health Management Group Co., Ltd. is a state-owned enterprise established by Shandong Port Group, offering comprehensive medical and health services. The group includes Qingdao Fuwai Cardiovascular Hospital (a tertiary specialist hospital), Rizhao Port Hospital (a secondary Class A general hospital), and Yantai Seaport Hospital (a secondary Class A general hospital). With over 1,800 beds and 360 senior professionals, it provides specialized care in cardiology, rehabilitation, orthopedics, urology, general surgery, neurology, ophthalmology, and health management. The group handles 1 million outpatient visits annually, discharges 50,000 patients, and performs 30,000 surgeries. The group aims to create a distinctive medical and health demonstration enterprise based on medical services, supported by health management, and focused on medical care.
Website Software